BOSTON, Mass. — The Boston region continues to rank among the world’s premier life sciences hubs even as laboratory vacancies climb and leasing activity slows, according to a new market analysis from Colliers that highlights both the strength of the local innovation ecosystem and the pressures reshaping the real estate market.
The report points to the region’s deep scientific workforce, extensive research funding, and strong venture capital activity as factors sustaining Boston’s global leadership in biotechnology and pharmaceutical innovation. The area supports more than 57,000 life sciences professionals and continues to attract major research investment, including roughly $3.4 billion in National Institutes of Health grants and about $8.1 billion in venture capital funding.
Over the past five years, Boston’s life sciences real estate footprint has expanded significantly, adding about 6 million square feet of laboratory and research space, an increase of roughly 20 percent. The expansion reflects the region’s rapid growth during the biotechnology boom of the early 2020s.
However, the surge in construction has also created a substantial amount of available lab space as new developments outpaced demand.
Since 2019, developers have delivered more than 26 million square feet of life sciences space across the Boston area. As a result, the market now includes roughly 16 million square feet of direct availability and another 3.7 million square feet listed for sublease, together accounting for more than one-third of the region’s total inventory.
The increased supply has shifted negotiating leverage toward tenants, providing companies with more options and improved bargaining power when signing leases. At the same time, elevated vacancy levels are putting pressure on asking rents across several key submarkets.
Boston is now among several major U.S. life sciences centers where vacancy rates exceed 20 percent, reflecting a broader national slowdown in leasing activity tied to macroeconomic challenges.
The Colliers report notes that the life sciences industry faced several financial headwinds in 2025, including weaker public market valuations, a slowdown in venture capital investment, and fewer initial public offerings. Data from PitchBook indicates that 2025 was tied for the second-lowest number of life sciences IPOs in the United States over the past 35 years. Venture capital funding totaled more than $33 billion during the year, roughly 25 percent below the average levels recorded between 2020 and 2022.
These financial constraints have prompted some biotechnology firms to reduce staffing levels, delay expansion plans, or scale back new leasing activity. As a result, life sciences real estate markets have recorded negative net absorption for two consecutive years.
Even so, Boston continues to attract major commitments from leading pharmaceutical and biotechnology companies.
Among the recent transactions highlighted in the report are Biogen’s planned 580,000-square-foot headquarters in Kendall Square, a 244,000-square-foot lease signed by Lila Sciences near Alewife Station, and a 75,000-square-foot lease secured by Eli Lilly in the Seaport District.
Such deals reflect the continued appeal of the Boston area for companies seeking proximity to major research universities, venture capital networks, and specialized scientific talent.
Boston remains one of the four dominant life sciences clusters in the United States, alongside the San Francisco Bay Area, San Diego, and Philadelphia. Together, those markets accounted for more than 75 percent of all new laboratory space delivered nationally during the past five years.
At the same time, the rapid pace of life sciences construction that characterized the previous expansion cycle is beginning to slow.
Across the United States, developers completed more than 50 million square feet of new life sciences space during the past five years, expanding national inventory by about 30 percent. But rising vacancy levels, higher borrowing costs, and tighter lending standards have prompted many developers to pause or cancel new projects.
Entering 2026, only about 7 million square feet of life sciences space remains under construction nationwide, with many of those projects tied to build-to-suit developments or facilities that secured significant preleasing commitments.
In some cases, developers have chosen to sell land originally planned for laboratory construction or redesign projects for alternative uses as market conditions evolve.
Despite the slowdown, industry analysts say early signs of stabilization are beginning to appear.
Valuations of publicly traded biotechnology companies have recovered significantly, now standing about 26 percent below their peak levels. That represents a notable improvement from April 2025, when valuations had fallen nearly 60 percent from their highs. Continued recovery could help revive IPO activity and venture capital investment, potentially allowing companies to expand research programs and lease additional space.
Several broader industry trends may also drive future demand for life sciences facilities, including efforts to onshore pharmaceutical manufacturing, supply chain resilience initiatives, and the growing commercial success of blockbuster therapies such as GLP-1 drugs.
The increasing use of artificial intelligence in scientific research and drug discovery is also expected to generate demand for advanced laboratories and technology-enabled research facilities.
While the life sciences real estate market is currently adjusting to a surge in supply and a temporary slowdown in demand, Boston’s concentration of research institutions, venture capital investors, and highly skilled scientists continues to reinforce its status as one of the world’s leading centers for biotechnology and pharmaceutical innovation.
As construction slows and market conditions gradually rebalance, analysts expect Boston to remain a central hub for scientific discovery, drug development, and life sciences entrepreneurship in the years ahead.
